Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $250.73, along with a high estimate of $300.00 and a low estimate of $170.00. A negative ...

Following promising phase 1 data, TCMCB07 is being further evaluated in a phase 2 trial for the treatment of patients with ...

Barclays analyst Tom O’Malley lowered the firm’s price target on Analog Devices (ADI) to $170 from $240 and keeps an Equal Weight rating on the ...